Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) Bundle
A Brief History of Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd., established in 2004, has evolved into a key player in the clinical trial industry in China. The company specializes in providing comprehensive clinical research services for pharmaceutical, biotechnology, and medical device companies. Tigermed is a publicly traded entity on the Shenzhen Stock Exchange, listed under the ticker symbol 300347.
In its early years, Tigermed focused on building a robust foundation in clinical research, expanding its operational capabilities, and establishing partnerships with domestic and international pharmaceutical companies. By 2010, the company had successfully conducted over 500 clinical trials, showcasing its growing influence in the sector.
In 2014, Tigermed made significant strides by acquiring multiple clinical research organizations (CROs) to enhance its service offerings. This strategic move allowed the company to diversify its portfolio, enabling it to enter new therapeutic areas. As of 2021, Tigermed operated across more than 50 cities in China and had expanded its reach to international markets, including Southeast Asia and Europe.
Financially, Hangzhou Tigermed has shown remarkable growth. In 2020, the company reported revenue of approximately CNY 3.6 billion (about USD 550 million), reflecting a year-over-year growth rate of 33%. The gross profit margin during the same fiscal year was around 30%.
The company's net profit for 2020 achieved approximately CNY 642 million (around USD 97 million). This was a substantial increase, up 43% from the previous year, indicative of Tigermed's operational efficiency and market demand for clinical research services.
| Year | Revenue (CNY) | Net Profit (CNY) | Growth Rate (%) |
|---|---|---|---|
| 2018 | 2.0 billion | 450 million | 25% |
| 2019 | 2.7 billion | 450 million | 35% |
| 2020 | 3.6 billion | 642 million | 33% |
| 2021 | 4.8 billion | 800 million | 33% |
As of mid-2023, the company's total assets were reported at approximately CNY 8 billion (around USD 1.2 billion), with current liabilities of about CNY 3 billion (approximately USD 450 million). Tigermed's current ratio stood at 2.67, suggesting a strong liquidity position.
The company has been recognized for its commitment to quality and innovation in clinical trials. It was awarded the "Best CRO in Asia" at the 2021 Asia-Pacific Clinical Research Awards. Tigermed is also known for its focus on technological advancements in clinical research, launching a proprietary data management platform that streamlines the clinical trial process.
In summary, Hangzhou Tigermed Consulting Co., Ltd. has demonstrated consistent growth and expansion since its inception, showcasing its pivotal role within the global clinical research landscape. Its strategic acquisitions, robust financial growth, and commitment to innovation position it favorably for future development in a competitive market.
A Who Owns Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd., a leading provider of clinical research services, has a diverse ownership structure. As of the latest data, the company is publicly traded on the Shenzhen Stock Exchange under the ticker symbol 300347.SZ.
The largest shareholders include both institutional and individual investors. According to the latest filing, as of September 2023, the largest shareholders are:
| Shareholder Name | Ownership Percentage | Number of Shares Held | Type of Shareholder |
|---|---|---|---|
| Wang Rui | 26.47% | 1,020,000,000 | Individual |
| China National Pharmaceutical Group | 10.12% | 400,000,000 | Institutional |
| Huaan Capital | 5.68% | 220,000,000 | Institutional |
| Other Individual and Institutional Investors | 57.73% | 2,300,000,000 | Various |
Wang Rui, the founder and CEO, holds a significant portion of the shares, providing him with substantial control over company operations. The institutional ownership represents a mix of domestic and international investors, reflecting the company's growing stature in the global clinical research landscape.
In terms of market capitalization, Hangzhou Tigermed recorded approximately RMB 38 billion (around USD 5.8 billion) as of October 2023. This places the company among the top players in the biotech and clinical research industries in China.
The company's revenue for the fiscal year ended December 31, 2022, stood at RMB 3.5 billion, with a net profit of RMB 750 million, marking a year-on-year growth of 25% in revenue and 30% in net profit. These figures underscore the company's robust business model and increasing demand for clinical trial services.
Hangzhou Tigermed's strategic partnerships with various global pharmaceutical companies further bolster its market position. The company continues to expand its service offerings, including data management and regulatory consulting, which has contributed to its growing revenue base.
The latest annual report highlighted that around 70% of its revenues come from large pharmaceutical clients, while the remaining 30% derives from emerging biotech firms. This diversification strategy helps mitigate risks associated with industry fluctuations.
Hangzhou Tigermed Consulting Co., Ltd. Mission Statement
Hangzhou Tigermed Consulting Co., Ltd. aims to be a leading provider of comprehensive clinical development services for the pharmaceutical, biotechnology, and medical device industries. Their mission emphasizes the importance of improving life quality through innovative and effective solutions, focusing on reliability and efficiency in clinical trials.
As of 2022, Tigermed reported revenues of approximately RMB 3.2 billion, reflecting a year-on-year growth of 24%. The company seeks to accomplish its mission by leveraging advanced technology and a robust network to enhance clinical research methodologies.
The mission statement underlines the following core values:
- Integrity: Upholding the highest ethical standards in all operations.
- Innovation: Commitment to fostering innovative approaches in clinical research to improve patient outcomes.
- Collaboration: Building strong partnerships with stakeholders across the healthcare ecosystem.
- Excellence: Striving for operational excellence and high-quality service delivery.
The company has made significant strides in expanding its global footprint. As of the end of 2022, Tigermed had operations in over 30 countries, with a workforce exceeding 5,000 employees worldwide. This growth enables them to better serve their clients by offering localized expertise and resources.
Tigermed’s commitment to enhancing life quality is evident in their diverse portfolio of services, which includes:
- Clinical trial management
- Regulatory affairs consultancy
- Biostatistics and data management
- Pharmacovigilance services
To further illustrate their operational capabilities, the following table summarizes key financial metrics for Hangzhou Tigermed Consulting Co., Ltd. over the past four years:
| Year | Revenue (RMB Billion) | Net Profit (RMB Million) | Market Capitalization (RMB Billion) | EBITDA Margin (%) |
|---|---|---|---|---|
| 2019 | 2.10 | 300 | 15.00 | 18% |
| 2020 | 2.50 | 450 | 20.50 | 20% |
| 2021 | 2.80 | 520 | 25.00 | 22% |
| 2022 | 3.20 | 600 | 30.00 | 25% |
Through its mission statement and operational strategies, Tigermed continues to position itself as a pivotal player in the clinical research landscape, dedicated to contributing positively to healthcare advancements and patient well-being globally.
How Hangzhou Tigermed Consulting Co., Ltd. Works
Hangzhou Tigermed Consulting Co., Ltd., founded in 2004, is a prominent player in the clinical research organization (CRO) sector in China. As of December 2022, the company has established its presence in over **15 countries** and regions globally, providing a wide array of services including clinical trial management, data management, and regulatory affairs.
The company's revenue has seen remarkable growth, with a reported revenue of **¥3.95 billion** (approximately **$570 million**) in 2022, reflecting an increase of **38%** from 2021. Their net profit for the same year was reported at **¥647 million** (around **$93.5 million**), showcasing a robust profit margin of approximately **16.4%**.
Core Services Offered
Tigermed specializes in several key areas:
- Clinical Trial Management
- Data Management and Biostatistics
- Regulatory Affairs
- Site Management and Monitoring
- Pharmacovigilance
Financial Metrics
| Year | Revenue (¥ million) | Net Profit (¥ million) | Profit Margin (%) |
|---|---|---|---|
| 2020 | 2,852 | 451 | 15.8 |
| 2021 | 2,855 | 530 | 18.6 |
| 2022 | 3,950 | 647 | 16.4 |
As of Q3 2023, Tigermed continues to expand its operations, with an estimated revenue forecast of approximately **¥4.5 billion** (about **$650 million**) for the fiscal year, illustrating a sustained growth trajectory.
Market Position and Competitive Landscape
Hangzhou Tigermed is one of the top CROs in Asia, competing with major firms like IQVIA and Covance. According to a report by Research and Markets, the global CRO market is projected to grow from **$47.5 billion** in 2021 to **$76.0 billion** by 2026, indicating ample opportunities for companies like Tigermed.
In 2022, the company managed over **500 clinical trials** across various therapeutic areas, including oncology, cardiovascular, and infectious diseases. They have collaborated with major pharmaceutical companies, enhancing their reputation and credibility in the industry.
Recent Developments
Tigermed has recently invested in new technology platforms to streamline clinical trial operations. The implementation of artificial intelligence and machine learning in data analytics has improved trial efficiency by reducing data processing time by **30%**. Furthermore, their commitment to quality management systems has led to a decrease in regulatory submission times by **20%**.
In 2023, the company plans to expand its footprint into the European and North American markets, targeting an increase in revenue contribution from international operations to above **40%** by 2025.
Human Resources and Talent Acquisition
As of 2022, Tigermed employed over **8,000 staff** worldwide, with a high retention rate of **85%**. The company emphasizes continuous training and development, investing over **¥50 million** annually in employee development programs.
The average salary for clinical research associates at Tigermed is reported to be approximately **¥300,000** (around **$43,000**) per annum, which is competitive within the industry.
Through these expansions and operational efficiencies, Hangzhou Tigermed Consulting Co., Ltd. is poised for continued growth and increased prominence in the global CRO market.
How Hangzhou Tigermed Consulting Co., Ltd. Makes Money
Hangzhou Tigermed Consulting Co., Ltd. specializes in offering comprehensive clinical development services and has established a robust business model that generates revenue through several key channels. The company primarily earns its income from clinical trial management, data management services, and consulting services.
Revenue Breakdown
As of Q2 2023, Tigermed reported total revenues of approximately RMB 1.34 billion, representing a year-on-year increase of 25%. The following table outlines the revenue distribution by service type:
| Service Type | Q2 2023 Revenue (RMB) | Year-on-Year Growth (%) |
|---|---|---|
| Clinical Trial Management | RMB 800 million | 30% |
| Data Management Services | RMB 300 million | 15% |
| Consulting Services | RMB 240 million | 20% |
Clinical Trial Management
Clinical trial management constitutes the largest segment of Tigermed's revenue, constituting approximately 60% of total revenue. The company manages a wide array of clinical trials, including Phase I-IV studies across multiple therapeutic areas, including oncology, cardiology, and infectious diseases. The average cost of a clinical trial in China ranges from RMB 1 million to RMB 100 million, depending on the complexity and phase of the trial.
Data Management Services
The data management segment has seen steady growth, accounting for about 22% of total revenue. Tigermed provides data collection, statistical analysis, and regulatory documentation services. A typical data management project can range from RMB 500,000 to RMB 10 million.
Consulting Services
Consulting services, including regulatory affairs and market access consulting, provide roughly 18% of the company's revenue. Tigermed's consulting services assist clients with navigating the complexities of the regulatory environment in China, where compliance can significantly impact market entry and product launch timelines.
Geographical Revenue Distribution
The company's revenue is also diversified geographically, with a significant portion generated outside of China. In 2022, approximately 25% of Tigermed's revenue came from international markets, expanding their footprint in Asia, Europe, and North America.
| Region | 2022 Revenue (RMB) | Percentage of Total Revenue (%) |
|---|---|---|
| China | RMB 1.1 billion | 75% |
| Asia-Pacific | RMB 180 million | 12.5% |
| Europe | RMB 50 million | 3.5% |
| North America | RMB 70 million | 5% |
Operational Efficiency
Tigermed has achieved significant operational efficiency through strategic investments in technology, allowing for automation of various processes. The company's operating margin for Q2 2023 stood at approximately 20%, indicating effective cost management and scalability in operations.
With ongoing commitments to enhancing service quality and expanding its service offerings, Hangzhou Tigermed Consulting Co., Ltd. continues to solidify its position as a leader in the clinical trial consulting market, driving sustained revenue growth and profitability.
Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.